Venus Remedies Ltd Stock Hits Record High of Rs.872.8 on 2 Feb 2026

Record-Breaking Price Movement

On 2 Feb 2026, Venus Remedies Ltd's stock price surged to an intraday high of Rs.872.8, marking its highest-ever valuation. The stock opened with a notable gap up of 4.97%, reflecting strong momentum from preceding sessions. Despite closing the day with a decline of 3.66%, the stock remains well above its key moving averages, trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning highlights the stock’s sustained upward trend over multiple time frames.

The day’s trading range was broad, with the stock touching a low of Rs.808, down 2.82% intraday, before rallying to its peak. The price action indicates some profit-taking following five consecutive days of gains, yet the milestone of an all-time high remains a significant achievement for the company.

Strong Relative Performance Against Benchmarks

Venus Remedies Ltd has demonstrated remarkable outperformance relative to the broader market indices. Over the past year, the stock has delivered a return of 169.15%, vastly exceeding the Sensex’s 4.64% gain during the same period. Its three-month performance is even more striking, with an 84.24% increase compared to the Sensex’s decline of 3.38%. The stock’s one-week return of 10.27% also contrasts favourably with the Sensex’s marginal fall of 0.53%.

Longer-term data further emphasises the company’s market-beating credentials. Over three years, Venus Remedies Ltd has appreciated by 409.22%, dwarfing the Sensex’s 35.32% gain. Even over a decade, the stock’s 575.95% rise outpaces the Sensex’s 230.50% increase, underscoring a consistent pattern of value creation for shareholders.

Financial Strength and Operational Metrics

Venus Remedies Ltd’s financial metrics reflect a company in strong health. The firm reported a 96.37% growth in operating profit in the December 2025 quarter, continuing a streak of positive results for five consecutive quarters. The highest recorded PBDIT for a quarter stands at Rs.37.52 crores, signalling robust earnings quality.

Return on Capital Employed (ROCE) for the half-year period reached a peak of 13.99%, while the inventory turnover ratio hit 6.58 times, indicating efficient asset utilisation. The company’s Return on Equity (ROE) is a respectable 10.5%, supported by a conservative average debt-to-equity ratio of zero, highlighting a debt-free capital structure.

Valuation metrics show the stock trading at a Price to Book Value of 1.9, which is considered fair given its growth profile and profitability. The Price/Earnings to Growth (PEG) ratio stands at 0.1, reflecting the company’s earnings growth outpacing its price appreciation, a factor often associated with undervaluation relative to growth.

Institutional Investor Participation

Institutional investors have increased their stake by 0.67% over the previous quarter, now collectively holding 3.28% of the company’s shares. This growing institutional interest suggests confidence in the company’s fundamentals and long-term prospects, given these investors’ capacity for detailed fundamental analysis.

Market Position and Sector Context

Operating within the Pharmaceuticals & Biotechnology sector, Venus Remedies Ltd has outperformed its peers and the broader BSE500 index across multiple time horizons. Its premium valuation relative to sector averages is supported by consistent earnings growth and operational efficiency.

Despite the strong performance, the company’s net sales growth over the past five years has averaged 6.29% annually, indicating moderate top-line expansion. This suggests that the company’s profitability gains have been driven more by operational leverage and margin improvement than rapid revenue growth.

Mojo Score and Ratings

Venus Remedies Ltd holds a Mojo Score of 74.0, categorised as a Buy rating as of 1 Feb 2026, following a downgrade from a previous Strong Buy rating. The Market Cap Grade is 4, reflecting a mid-sized market capitalisation within its sector. This rating adjustment aligns with the company’s current valuation and recent price action, while still recognising its strong fundamentals and growth trajectory.

Recent Trading Dynamics

While the stock underperformed the sector by 3.29% on the day it hit its all-time high, this was against a backdrop of a 0.47% gain in the Sensex. The short-term pullback after a series of gains is a common market phenomenon and does not detract from the overall positive trend established over the past months and years.

Venus Remedies Ltd’s ability to sustain trading above all major moving averages indicates continued investor confidence and technical strength, which has supported the stock’s rise to record levels.

Summary

The achievement of an all-time high price of Rs.872.8 by Venus Remedies Ltd represents a significant milestone in the company’s market journey. Supported by strong financial results, efficient operations, and consistent outperformance relative to market benchmarks, the stock’s rise reflects a well-established growth story within the Pharmaceuticals & Biotechnology sector. Institutional participation and solid valuation metrics further underpin the company’s standing as it continues to build on its track record of delivering shareholder value.

While the stock experienced a modest correction on the day of the record high, its long-term trend remains firmly positive, supported by robust fundamentals and a debt-free balance sheet. The company’s steady improvement in profitability and operational efficiency has been key to this sustained upward trajectory.

Venus Remedies Ltd’s performance over multiple time frames, including one, three, five, and ten years, highlights its capacity to generate substantial returns, significantly outpacing broader market indices and sector peers.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →